Steward Partners Investment Advisory LLC trimmed its stake in shares of Allergan plc (NYSE:AGN) by 87.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,249 shares of the company’s stock after selling 8,392 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Allergan were worth $209,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in AGN. Liberty Wealth Management LLC lifted its stake in Allergan by 108.8% in the 1st quarter. Liberty Wealth Management LLC now owns 190 shares of the company’s stock worth $27,000 after acquiring an additional 99 shares in the last quarter. Legacy Bridge LLC acquired a new position in Allergan in the 1st quarter worth about $27,000. Patriot Financial Group Insurance Agency LLC increased its position in Allergan by 2,162.5% in the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 181 shares of the company’s stock worth $27,000 after purchasing an additional 173 shares during the last quarter. Investors Research Corp acquired a new position in Allergan in the 1st quarter worth about $29,000. Finally, Evolution Wealth Advisors LLC acquired a new position in Allergan in the 2nd quarter worth about $30,000. 77.81% of the stock is owned by institutional investors and hedge funds.

AGN opened at $159.94 on Wednesday. The firm has a market cap of $52.43 billion, a price-to-earnings ratio of 9.58, a P/E/G ratio of 1.65 and a beta of 1.63. The firm has a 50 day simple moving average of $163.66. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.69 and a quick ratio of 1.49. Allergan plc has a 12-month low of $114.27 and a 12-month high of $197.00.

Allergan (NYSE:AGN) last released its earnings results on Tuesday, August 6th. The company reported $4.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.34 by $0.04. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. The firm had revenue of $4.09 billion for the quarter, compared to analyst estimates of $3.93 billion. During the same quarter last year, the firm posted $4.42 EPS. The company’s revenue was down .8% on a year-over-year basis. As a group, equities research analysts expect that Allergan plc will post 16.64 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 13th. Shareholders of record on Tuesday, August 13th will be given a $0.74 dividend. The ex-dividend date is Monday, August 12th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.85%. Allergan’s dividend payout ratio is currently 17.74%.

Several research analysts have weighed in on AGN shares. Cantor Fitzgerald upped their target price on Allergan from $125.00 to $165.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Svb Leerink reaffirmed a “market perform” rating and issued a $188.00 target price (down from $217.00) on shares of Allergan in a research report on Thursday, July 18th. UBS Group lowered their price objective on Allergan from $173.00 to $172.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Barclays increased their price objective on Allergan from $176.00 to $188.00 and gave the company an “equal weight” rating in a report on Wednesday, August 7th. Finally, Sanford C. Bernstein lowered Allergan from an “outperform” rating to a “market perform” rating and set a $166.08 price objective on the stock. in a report on Tuesday, July 16th. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $180.00.

Allergan Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Featured Article: What is the S&P 500 Index?

Want to see what other hedge funds are holding AGN? Visit to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with's FREE daily email newsletter.